Background: Idiopathic intracranial hypertension (IIH) occurs throughout the world with an estimated incidence of one to three per 100,000 population per year. It occurs most commonly in obese young women, but the cause is unknown. It presents a significant threat to sight and is associated with severe morbidity in the form of headaches in the majority of cases. Several different treatments have been proposed, ranging from relatively conservative measures such as diuretic therapy to more invasive treatments such as optic nerve sheath fenestration or lumbo-peritoneal shunting.
Objectives: The aim of this review is to assess the evidence from controlled trials looking at the various treatments used for idiopathic intracranial hypertension with a view to producing an evidence-based treatment strategy.
Search Strategy: We searched the Cochrane Controlled Trials Register - CENTRAL/CCTR (which contains the Cochrane Eyes and Vision Group specialised register) on the Cochrane Library Issue 2, 2002, MEDLINE (1966 to March 2002) and EMBASE (1980 to February 2002).
Selection Criteria: We included only randomised controlled trials in which any intervention used to treat idiopathic intracranial hypertension had been compared to placebo or to another form of treatment in people with a clinical diagnosis of idiopathic intracranial hypertension.
Data Collection And Analysis: Two reviewers independently assessed the search results for trials to be included in the review. Discrepancies were resolved by discussion. Since no trials met our inclusion criteria, no assessment of quality or meta-analysis was undertaken.
Main Results: No randomised controlled trials were found that met the inclusion criteria.
Reviewer's Conclusions: There is insufficient information to generate an evidence-based management strategy for idiopathic intracranial hypertension. Of the various treatments available, there is inadequate information regarding which are truly beneficial and which are potentially harmful. Properly designed and executed trials are needed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/14651858.CD003434 | DOI Listing |
Cureus
December 2024
Emergency, Royal Victorian Eye and Ear Hospital, Melbourne, AUS.
Idiopathic intracranial hypertension (IIH) is a neurological disorder characterized by chronic headaches, cognitive difficulties, reduced quality of life, and rarely irreversible visual loss. Community diagnosis is often challenging due to unfamiliarity with current guidelines and a lack of clinical experience, leading to misdiagnosis and treatment delays, which can negatively impact visual recovery and quality of life. Our study examined the time to diagnosis and investigated the barriers to timely diagnosis in adults with newly diagnosed IIH.
View Article and Find Full Text PDFClin Case Rep
February 2025
Department of Pediatrics, Division of Pediatric Neurology Children's Medical Center, Pediatrics Center of Excellent, Tehran University of Medical Sciences Tehran Iran.
A critical clinical consideration, in addition to other common risk factors predisposing individuals to idiopathic intracranial hypertension (IIH), involves the potential co-occurrence of increased intracranial pressure and elevated cerebrospinal fluid protein levels in the presence of underlying malignancies. Primary diffuse leptomeningeal melanomatosis, an exceptionally rare condition with few reported cases in the pediatric population, illustrates this scenario. Timely decision-making based on clinical suspicion to perform a biopsy and involving a skilled pathologist for accurate reporting are essential steps toward achieving a definitive diagnosis.
View Article and Find Full Text PDFBiomedicines
December 2024
Department of Neurology, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, 34147 Istanbul, Turkey.
The course of relapsing-remitting multiple sclerosis (RRMS) is highly variable and there is a lack of effective prognostic biomarkers. This study aimed to assess the potential prognostic value of the chemokines B lymphocyte chemoattractant molecule (CXCL13), eotaxin-1 (CCL11), and macrophage inflammatory protein 3-alpha (CCL20) in RRMS. Forty-two patients with MS were enrolled, along with 22 controls, 12 of the controls were idiopathic intracranial hypertension (IIH) patients, and 10 of the controls were other neurologic diseases (OND).
View Article and Find Full Text PDFEye (Lond)
January 2025
Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, B15 2TT, UK.
Background/objectives: Idiopathic intracranial hypertension (IIH) is a disease which threatens vision and causes disabling headaches, affecting women of childbearing age with obesity. It is characterised by raised intracranial pressure (ICP), measured invasively either with lumbar punctures or intracranially-inserted monitors. There is an unmet clinical need to develop non-invasive means to assess ICP.
View Article and Find Full Text PDFClin Neurol Neurosurg
January 2025
Doctor of Neurology, Celal Bayar University, Department of Neurology, Manisa 45000, Turkey. Electronic address:
Purpose: Idiopathic Intracranial Hypertension (IIH) is marked by elevated intracranial pressure without an identifiable cause. This study aimed to compare predictive factors between two IIH groups: those experiencing remission (single attack) and those developing migrainous headaches, in order to identify factors influencing the disease's progression.
Methods: This retrospective study was conducted after obtaining ethics committee approval.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!